Literature DB >> 18188527

The effects of raloxifene and tibolone on homocysteine and vascular histopathological changes.

M Bayram1, G Ozer, H Kalender, N Kabakci, U Kisa, Y Ozkan.   

Abstract

The aim of the present study was to examine the effects of raloxifene (RLX) and tibolone (TBN) on plasma homocysteine (Hcy) levels and their relationship with atherosclerotic changes in the walls of the carotid artery in ovariectomised rats. Thirty surgically ovariectomised Wistar albino rats after a menopausal period of 6 cycles were randomly assigned to receive RLX 0.01 mg/kg/day (n=10), TBN 0.04 mg/kg/day (n=10) and the same dose of placebo (n=10) for 6 cycles. Serum levels of vitamin B12, folate and Hcy were measured and carotid arteries were examined histopathologically following the termination of treatment. Hcy levels were 3.27+/-0.97, 2.57+/-0.32 and 2.28+/-0.12 micromol/l, Vitamin B12 levels were 901.90+/-239.76, 694.70+/-112.20 and 631+/-309.44 pg/ml and folate levels were 73.80+/-12.71, 72.51+/-7.05 and 84.79+/-20.82 ng/ml in receiving RLX, TBN and placebo respectively. Hcy levels were increased by RLX vs. placebo (P=0.006) but not by TBN vs. placebo (P=0.070). Vitamin B12 levels were found to be elevated by TBN vs. the control group (P=0.041) but not by RLX vs. placebo (P=0.059). Histopathological examination of carotid arteries from rats receiving both RLX and TBN revealed no difference vs. placebo. Data obtained from the study support the view that neither RLX nor TBN appears to have a primary protective effect on vascular disease by effecting the metabolism of Hcy at menopause.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18188527     DOI: 10.1007/s10238-007-0139-6

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  25 in total

Review 1.  Hormone replacement therapy and stroke: risk, protection or no effect?

Authors:  A Paganini-Hill
Journal:  Maturitas       Date:  2001-05-30       Impact factor: 4.342

2.  Plasma homocysteine levels and mortality in patients with coronary artery disease.

Authors:  O Nygård; J E Nordrehaug; H Refsum; P M Ueland; M Farstad; S E Vollset
Journal:  N Engl J Med       Date:  1997-07-24       Impact factor: 91.245

Review 3.  Estrogen and progestogen therapy in postmenopausal women.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

4.  The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial.

Authors:  B W Walsh; S Paul; R A Wild; R A Dean; R P Tracy; D A Cox; P W Anderson
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

5.  Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1998-03-21

6.  Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells.

Authors:  A Majors; L A Ehrhart; E H Pezacka
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-10       Impact factor: 8.311

7.  Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.

Authors:  K A Hajjar
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

8.  Effects of tibolone on plasma homocysteine levels in postmenopausal women.

Authors:  Husnu Celik; Ahmet Ayar; Niyazi Tug; Gürkan Cikim; Nermin Kilic; Cem Parmaksiz
Journal:  Fertil Steril       Date:  2002-08       Impact factor: 7.329

Review 9.  Clinical usefulness of plasma homocysteine in vascular disease.

Authors:  Graeme J Hankey; John W Eikelboom; Wai Khoon Ho; Frank M van Bockxmeer
Journal:  Med J Aust       Date:  2004-09-20       Impact factor: 7.738

10.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Authors:  C J Boushey; S A Beresford; G S Omenn; A G Motulsky
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.